Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis.
作者信息
Chatterjee Sanjoy, Arun Indu, Agrawal Sanjit, Arunsingh Moses, Mallick Indranil, Ahmed Rosina
机构信息
Tata Medical Center, Kolkata, India.
出版信息
J Glob Oncol. 2016 Sep 7;3(2):180-181. doi: 10.1200/JGO.2016.006635. eCollection 2017 Apr.
Abstract
摘要
相似文献
1
Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis.
J Glob Oncol. 2016 Sep 7;3(2):180-181. doi: 10.1200/JGO.2016.006635. eCollection 2017 Apr.
2
Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.
J Glob Oncol. 2016 Jun 29;2(6):412-421. doi: 10.1200/JGO.2016.005397. eCollection 2016 Dec.
3
Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
PLoS One. 2016 Aug 31;11(8):e0160148. doi: 10.1371/journal.pone.0160148. eCollection 2016.
4
Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.
Int J Biol Sci. 2016 Dec 7;12(12):1568-1577. doi: 10.7150/ijbs.16874. eCollection 2016.
5
Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.
Niger J Clin Pract. 2015 May-Jun;18(3):381-6. doi: 10.4103/1119-3077.153248.
6
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2014 Dec;148(3):467-76. doi: 10.1007/s10549-014-3185-2. Epub 2014 Nov 1.
7
Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis.
Clin Genet. 2014 Jan;85(1):43-8. doi: 10.1111/cge.12270. Epub 2013 Oct 3.
8
The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
Tumour Biol. 2017 Oct;39(10):1010428317713390. doi: 10.1177/1010428317713390.
9
The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients.
Cancer Treat Rev. 2016 Jun;47:12-21. doi: 10.1016/j.ctrv.2016.05.001. Epub 2016 May 11.
10
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Breast Cancer Res. 2015 Mar 20;17:43. doi: 10.1186/s13058-015-0550-y.
引用本文的文献
1
Consensus on contentious issues relevant for breast cancer management for the Indian scenario: Statements following a multicentre expert group meeting.
Indian J Med Res. 2021 Aug;154(2):180-188. doi: 10.4103/ijmr.IJMR_2630_20.
2
PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC).
Ecancermedicalscience. 2021 Apr 6;15:1217. doi: 10.3332/ecancer.2021.1217. eCollection 2021.
3
Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer.
JCO Glob Oncol. 2020 Jul;6:1052-1062. doi: 10.1200/GO.20.00054.
本文引用的文献
1
Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.
J Glob Oncol. 2016 Jun 29;2(6):412-421. doi: 10.1200/JGO.2016.005397. eCollection 2016 Dec.
2
Outcomes Following a Moderately Hypofractionated Adjuvant Radiation (START B Type) Schedule for Breast Cancer in an Unscreened Non-Caucasian Population.
Clin Oncol (R Coll Radiol). 2016 Oct;28(10):e165-72. doi: 10.1016/j.clon.2016.05.008. Epub 2016 Jun 28.
3
Triple negative breast cancer: an Indian perspective.
Breast Cancer (Dove Med Press). 2015 Aug 14;7:239-43. doi: 10.2147/BCTT.S85442. eCollection 2015.
4
Overview of automated immunohistochemistry.
Arch Pathol Lab Med. 2014 Dec;138(12):1578-82. doi: 10.5858/arpa.2014-0083-RA.
5
Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India.
Asian Pac J Cancer Prev. 2014;15(6):2505-10. doi: 10.7314/apjcp.2014.15.6.2505.
6
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7.
7
Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
Asian Pac J Cancer Prev. 2011;12(3):625-9.
8
Current issues in ER and HER2 testing by IHC in breast cancer.
Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34.
9
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
J Clin Oncol. 2006 Dec 20;24(36):5637-44. doi: 10.1200/JCO.2005.05.4155. Epub 2006 Nov 20.
Zotero 插件